Novel Therapy Target in Metastatic Prostate Cancer
ConditionProstate Neoplasms
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorFudan University
About this trial
The aim of this study is to use multiomics sequencing to explore the molecular characteristics of metastatic prostate cancer (mPCa), especially metastatic castration-resistant prostate cancer (mCRPC). At the same time, mCRPC models will be constructed, including organoids and animal models, serving as a basic and translational research platform to help identify novel drug targets for mPCa.
Eligibility criteria
Qualifiers
Histologically confirmed prostate cancer
metastatic disease confirmed by image examination
Patients who can undergo surgery or biopsy for prostate cancer
Able to provide informed consent
Disqualifiers
Patients diagnosed with other types of cancer besides prostate cancer
Not accessible to surgery sample
Patients fail to provide informed consent
Other situation that researchers think are unsuitable for this study
Trial design
Treatments tested in this trial
- Tissue
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov